Citations (58)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Marios Karvouniaris, Konstantinos Pontikis, Thomas Nitsotolis & Garyphallia Poulakou. (2021) New perspectives in the antibiotic treatment of mechanically ventilated patients with infections from Gram-negatives. Expert Review of Anti-infective Therapy 19:7, pages 825-844.
Read now
Read now
Mohammad Hadi Fakoor, Seyed Latif Mousavi Gargari, Parviz Owlia & Azar Sabokbar. (2020) Protective Efficacy of the OprF/OprI/PcrV Recombinant Chimeric Protein Against Pseudomonas aeruginosa in the Burned BALB/c Mouse Model. Infection and Drug Resistance 13, pages 1651-1661.
Read now
Read now
Austin Hoggarth, Andrew Weaver, Qinqin Pu, Ting Huang, Jacob Schettler, Feng Chen, Xiefang Yuan & Min Wu. (2019) Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa. Drug Design, Development and Therapy 13, pages 909-924.
Read now
Read now
Bilal Aslam, Wei Wang, Muhammad Imran Arshad, Mohsin Khurshid, Saima Muzammil, Muhammad Hidayat Rasool, Muhammad Atif Nisar, Ruman Farooq Alvi, Muhammad Aamir Aslam, Muhammad Usman Qamar, Muhammad Khalid Farooq Salamat & Zulqarnain Baloch. (2018) Antibiotic resistance: a rundown of a global crisis. Infection and Drug Resistance 11, pages 1645-1658.
Read now
Read now
Articles from other publishers (54)
Keita Inoue, Mao Kinoshita, Kentaro Muranishi, Junya Ohara, Kazuki Sudo, Ken Kawaguchi, Masaru Shimizu, Yoshifumi Naito, Kiyoshi Moriyama & Teiji Sawa. (2023) Effect of a Novel Trivalent Vaccine Formulation against Acute Lung Injury Caused by Pseudomonas aeruginosa. Vaccines 11:6, pages 1088.
Crossref
Crossref
Moamen M. Elmassry, Jane A. Colmer-Hamood, Jonathan Kopel, Michael J. San Francisco & Abdul N. Hamood. (2023) Anti-Pseudomonas aeruginosa Vaccines and Therapies: An Assessment of Clinical Trials. Microorganisms 11:4, pages 916.
Crossref
Crossref
С. А. Деркач, Н. М. Куцай, Н. І. Городницька & Н. І. Скляр. (2023) ПРОТЕКТИВНІ ВЛАСТИВОСТІ ЗРАЗКІВ СИНЬОГНІЙНОЇ АВТОВАКЦИНИ. Інфекційні хвороби:1, pages 35-39.
Crossref
Crossref
Kaushita Banerjee & Harishkumar Madhyastha. 2023. Current Trends in the Identification and Development of Antimicrobial Agents. Current Trends in the Identification and Development of Antimicrobial Agents
304
338
.
Vincenzo Costanzo & Giovanni N. Roviello. (2023) The Potential Role of Vaccines in Preventing Antimicrobial Resistance (AMR): An Update and Future Perspectives. Vaccines 11:2, pages 333.
Crossref
Crossref
Phillip R. Pittman, Gunnstein Norheim, Benjamin Pierson & Fernando B. Guerena. 2023. Plotkin's Vaccines. Plotkin's Vaccines
172
190.e9
.
Catherine B. Blackwood, Margalida Mateu-Borrás, Emel Sen-Kilic, Gage M. Pyles, Sarah Jo Miller, Kelly L. Weaver, William T. Witt, Annalisa B. Huckaby, Jason Kang, Courtney E. Chandler, Robert K. Ernst, F. Heath Damron & Mariette Barbier. (2022) Bordetella pertussis whole cell immunization protects against Pseudomonas aeruginosa infections. npj Vaccines 7:1.
Crossref
Crossref
Mohammad Omar Faruk Shaikh, Matthew M. Schaefers, Christina Merakou, Marco DiBlasi, Sarah Bonney, Tiffany Liao, David Zurakowski, Margaret Kehl, David E. Tabor, Antonio DiGiandomenico & Gregory P. Priebe. (2022) Multicomponent Pseudomonas aeruginosa Vaccines Eliciting Th17 Cells and Functional Antibody Responses Confer Enhanced Protection against Experimental Acute Pneumonia in Mice. Infection and Immunity 90:10.
Crossref
Crossref
Matthew Killough, Aoife Rodgers & Rebecca Ingram. (2022) Pseudomonas aeruginosa: Recent Advances in Vaccine Development. Vaccines 10:7, pages 1100.
Crossref
Crossref
Mohammad Reza Rahbar, Shaden M. H. Mubarak, Anahita Hessami, Bahman Khalesi, Navid Pourzardosht, Saeed Khalili, Kobra Ahmadi Zanoos & Abolfazl Jahangiri. (2022) A unique antigen against SARS-CoV-2, Acinetobacter baumannii, and Pseudomonas aeruginosa. Scientific Reports 12:1.
Crossref
Crossref
Sara Russo Krauss, Marija Barbateskovic, Sarah Louise Klingenberg, Snezana Djurisic, Sesilje Bondo Petersen, Mette Kenfelt, De Zhao Kong, Janus C Jakobsen & Christian Gluud. (2022) Aluminium adjuvants versus placebo or no intervention in vaccine randomised clinical trials: a systematic review with meta-analysis and Trial Sequential Analysis. BMJ Open 12:6, pages e058795.
Crossref
Crossref
Fatemeh Esmaeilzadeh & Shirin Mahmoodi. (2022) A Novel Design of Multi-epitope Peptide Vaccine Against Pseudomonas
aeruginosa. Letters in Drug Design & Discovery 19:4, pages 304-313.
Crossref
Crossref
Robert J. Hart & Lisa A. Morici. (2022) Vaccination to Prevent Pseudomonas aeruginosa Bloodstream Infections. Frontiers in Microbiology 13.
Crossref
Crossref
Monika Yadav. 2022. Comprehensive Gut Microbiota. Comprehensive Gut Microbiota
368
389
.
Marcin Michalik, Bardya Djahanschiri, Jack C. Leo & Dirk Linke. 2022. Vaccine Design. Vaccine Design
45
71
.
Sidra Irum, Saadia Andleeb, Amjad Ali, Muhammad Ibrahim Rashid & Mahnoor Majid. (2021) Quest for Novel Preventive and Therapeutic Options Against Multidrug-Resistant Pseudomonas aeruginosa. International Journal of Peptide Research and Therapeutics 27:4, pages 2313-2331.
Crossref
Crossref
Jintao Zou, Haiming Jing, Xiaoli Zhang, Yiheng Liu, Zhuo Zhao, Lianli Duan, Yue Yuan, Zhifu Chen, Qiang Gou, Qingshan Xiong, Sisi Li, Feng Yang, Hao Zeng, Quanming Zou & Jinyong Zhang. (2021) α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants. Frontiers in Immunology 12.
Crossref
Crossref
Sílvia A. Sousa, António M. M. Seixas, Joana M. M. Marques & Jorge H. Leitão. (2021) Immunization and Immunotherapy Approaches against Pseudomonas aeruginosa and Burkholderia cepacia Complex Infections. Vaccines 9:6, pages 670.
Crossref
Crossref
Giada Antonelli, Luigia Cappelli, Paolo Cinelli, Rossella Cuffaro, Benedetta Manca, Sonia Nicchi, Serena Tondi, Giacomo Vezzani, Viola Viviani, Isabel Delany, Maria Scarselli & Francesca Schiavetti. (2021) Strategies to Tackle Antimicrobial Resistance: The Example of Escherichia coli and Pseudomonas aeruginosa. International Journal of Molecular Sciences 22:9, pages 4943.
Crossref
Crossref
Absar Talat & Asad U Khan. (2021) Vaccines against antimicrobial resistance: a promising escape route for multidrug resistance. Pharmaceutical Patent Analyst.
Crossref
Crossref
Luke N. Yaeger, Victoria E. Coles, Derek C. K. Chan & Lori L. Burrows. (2021)
How to kill
Pseudomonas
—emerging therapies for a challenging pathogen
. Annals of the New York Academy of Sciences.
Crossref
Crossref
Emel Sen-Kilic, Catherine B. Blackwood, Annalisa B. Huckaby, Alexander M. Horspool, Kelly L. Weaver, Aaron C. Malkowski, William T. Witt, Justin R. Bevere, F. Heath Damron & Mariette Barbier. (2021) Defining the Mechanistic Correlates of Protection Conferred by Whole-Cell Vaccination against Pseudomonas aeruginosa Acute Murine Pneumonia. Infection and Immunity 89:2.
Crossref
Crossref
Fattaneh Sabzehali, Hamzeh Rahimi, Hossein Goudarzi, Mehdi Goudarzi, Mohammad Hossein Yoosefi Izad, Alireza Salimi Chirani, Seyed Amir Jalali & Ebrahim Faghihloo. (2021) Functional engineering of OprF-OprI-PopB as a chimeric immunogen and its cross-protective evaluation with GM-CSF against Pseudomonas aeruginosa: A comprehensive immunoinformatics evaluation. Informatics in Medicine Unlocked 25, pages 100673.
Crossref
Crossref
Christopher Adlbrecht, Raphael Wurm, Pieter Depuydt, Herbert Spapen, Jose A. Lorente, Thomas Staudinger, Jacques Creteur, Christian Zauner, Andreas Meier-Hellmann, Philipp Eller, Margot Vander Laenen, Zsolt Molnár, István Várkonyi, Bernhard Schaaf, Mária Héjja, Vladimír Šrámek, Hauke Schneider, Niranjan Kanesa-thasan, Susanne Eder-Lingelbach, Anton Klingler, Katrin Dubischar, Nina Wressnigg & Jordi Rello. (2020) Efficacy, immunogenicity, and safety of IC43 recombinant Pseudomonas aeruginosa vaccine in mechanically ventilated intensive care patients—a randomized clinical trial. Critical Care 24:1.
Crossref
Crossref
Haiming Jing, Xiaoli Zhang, Jintao Zou, Yue Yuan, Zhifu Chen, Dong Liu, Weiru Wu, Feng Yang, Dongshui Lu, Quanming Zou & Jinyong Zhang. (2020) Oligomerization of IC43 resulted in improved immunogenicity and protective efficacy against Pseudomonas aeruginosa lung infection. International Journal of Biological Macromolecules 159, pages 174-182.
Crossref
Crossref
Mohammed Bahey-El-Din, Shaymaa Abdelrahman Mohamed, Salah Ahmed Sheweita, Medhat Haroun & Taha Ibrahim Zaghloul. (2020) Recombinant N-terminal outer membrane porin (OprF) of Pseudomonas aeruginosa is a promising vaccine candidate against both P. aeruginosa and some strains of Acinetobacter baumannii. International Journal of Medical Microbiology 310:3, pages 151415.
Crossref
Crossref
Filomena Nazzaro, Florinda Fratianni, Antonio d’Acierno, Raffaele Coppola, Fernando Jesus Ayala-Zavala, Adriano Gomez da Cruz & Vincenzo De Feo. 2020. Essential Oils - Oils of Nature. Essential Oils - Oils of Nature.
Irene Bianconi, Beatriz Alcalá-Franco, Maria Scarselli, Mattia Dalsass, Scilla Buccato, Annalisa Colaprico, Sara Marchi, Vega Masignani & Alessandra Bragonzi. (2019) Genome-Based Approach Delivers Vaccine Candidates Against Pseudomonas aeruginosa. Frontiers in Immunology 9.
Crossref
Crossref
Dahlia N. Amato, Douglas V. Amato, Yetunde Adewunmi, Olga V. Mavrodi, Keith H. Parsons, Sarah N. Swilley, Dwaine A. Braasch, William D. Walker, Dmitri V. Mavrodi & Derek L. Patton. (2018) Using Aldehyde Synergism To Direct the Design of Degradable Pro-Antimicrobial Networks. ACS Applied Bio Materials 1:6, pages 1983-1991.
Crossref
Crossref
Yoshifumi Naito, Saeko Hamaoka, Mao Kinoshita, Atsushi Kainuma, Masaru Shimizu, Hideya Katoh, Kiyoshi Moriyama, Ken J. Ishii & Teiji Sawa. (2018)
The protective effects of nasal PcrV-CpG oligonucleotide vaccination against
Pseudomonas aeruginosa
pneumonia
. Microbiology and Immunology 62:12, pages 774-785.
Crossref
Crossref
Christina MerakouMatthew M. SchaefersGregory P. Priebe. (2018)
Progress Toward the Elusive
Pseudomonas aeruginosa
Vaccine
. Surgical Infections 19:8, pages 757-768.
Crossref
Crossref
Feng Yang, Jiang Gu, Jintao Zou, Langhuan Lei, Haiming Jing, Jin Zhang, Hao Zeng, Quanming Zou, Fenglin Lv & Jinyong Zhang. (2018) PA0833 Is an OmpA C-Like Protein That Confers Protection Against Pseudomonas aeruginosa Infection. Frontiers in Microbiology 9.
Crossref
Crossref
Phillip R. Pittman & Stanley A. Plotkin. 2018. Plotkin's Vaccines. Plotkin's Vaccines
149
160.e7
.
Yang Zhang, Jie Su & Donghui Wu. 2017. Physiology and Pathology of Immunology. Physiology and Pathology of Immunology.
Jordi Rello, Claus-Georg Krenn, Gottfried Locker, Ernst Pilger, Christian Madl, Laura Balica, Thierry Dugernier, Pierre-Francois Laterre, Herbert Spapen, Pieter Depuydt, Jean-Louis Vincent, Lajos Bogár, Zsuzsanna Szabó, Barbara Völgyes, Rafael Máñez, Nahit Cakar, Atilla Ramazanoglu, Arzu Topeli, Maria A. Mastruzzo, Abel Jasovich, Christian G. Remolif, Liliana del Carmen Soria, Max A. Andresen Hernandez, Carolina Ruiz Balart, Ildikó Krémer, Zsolt Molnár, Frank von Sonnenburg, Arthur Lyons, Michael Joannidis, Heinz Burgmann, Tobias Welte, Anton Klingler, Romana Hochreiter & Kerstin Westritschnig. (2017) A randomized placebo-controlled phase II study of a Pseudomonas vaccine in ventilated ICU patients. Critical Care 21:1.
Crossref
Crossref
P. Loubet & O. Launay. (2017) Vaccination de l’adulte : données générales, actualités et perspectives. La Revue de Médecine Interne 38:11, pages 749-759.
Crossref
Crossref
Chen Gao, Feng Yang, Ying Wang, Yaling Liao, Jinyong Zhang, Hao Zeng, Quanming Zou & Jiang Gu. (2017) Vaccination with a recombinant OprL fragment induces a Th17 response and confers serotype-independent protection against Pseudomonas aeruginosa infection in mice. Clinical Immunology 183, pages 354-363.
Crossref
Crossref
Feng Yang, Jiang Gu, Liuyang Yang, Chen Gao, Haiming Jing, Ying Wang, Hao Zeng, Quanming Zou, Fenglin Lv & Jinyong Zhang. (2017) Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models. Scientific Reports 7:1.
Crossref
Crossref
Jason W. Lee, Natalie A. Parlane, D. Neil Wedlock & Bernd H. A. Rehm. (2017) Bioengineering a bacterial pathogen to assemble its own particulate vaccine capable of inducing cellular immunity. Scientific Reports 7:1.
Crossref
Crossref
Saeko Hamaoka, Yoshifumi Naito, Hideya Katoh, Masaru Shimizu, Mao Kinoshita, Koichi Akiyama, Atsushi Kainuma, Kiyoshi Moriyama, Ken J. Ishii & Teiji Sawa. (2017)
Efficacy comparison of adjuvants in PcrV vaccine against
Pseudomonas aeruginosa
pneumonia
. Microbiology and Immunology 61:2, pages 64-74.
Crossref
Crossref
Gabor Zilahi, Antonio Artigas & Ignacio Martin-Loeches. (2016) What’s new in multidrug-resistant pathogens in the ICU?. Annals of Intensive Care 6:1.
Crossref
Crossref
Mathias W. Pletz, Julia Uebele, Karen Götz, Stefan Hagel & Isabelle Bekeredjian-Ding. (2016) Vaccines against major ICU pathogens. Current Opinion in Critical Care 22:5, pages 470-476.
Crossref
Crossref
Thomas J. An, Michael A. Benvenuti, Megan E. Mignemi, Isaac P. Thomsen & Jonathan G. Schoenecker. (2016) Pediatric Musculoskeletal Infection. JBJS Reviews 4:9.
Crossref
Crossref
Xian Yu, Yan Wang, Yifan Xia, Lijuan Zhang, Qin Yang & Jun Lei. (2016) A DNA vaccine encoding VP22 of herpes simplex virus type I (HSV-1) and OprF confers enhanced protection from Pseudomonas aeruginosa in mice. Vaccine 34:37, pages 4399-4405.
Crossref
Crossref
Marc Lipsitch & George R. Siber. (2016) How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?. mBio 7:3.
Crossref
Crossref
Nicole Bézay, Andrea Ayad, Katrin Dubischar, Christa Firbas, Romana Hochreiter, Sigrid Kiermayr, István Kiss, Fritz Pinl, Bernd Jilma & Kerstin Westritschnig. (2016) Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine 34:23, pages 2585-2592.
Crossref
Crossref
Jaideep S. Talwalkar & Thomas S. Murray. (2016) The Approach to Pseudomonas aeruginosa in Cystic Fibrosis. Clinics in Chest Medicine 37:1, pages 69-81.
Crossref
Crossref
Meritxell García-Quintanilla, Marina R. Pulido, Marta Carretero-Ledesma & Michael J. McConnell. (2016) Vaccines for Antibiotic-Resistant Bacteria: Possibility or Pipe Dream?. Trends in Pharmacological Sciences 37:2, pages 143-152.
Crossref
Crossref
Lloyd Czaplewski, Richard Bax, Martha Clokie, Mike Dawson, Heather Fairhead, Vincent A Fischetti, Simon Foster, Brendan F Gilmore, Robert E W Hancock, David Harper, Ian R Henderson, Kai Hilpert, Brian V Jones, Aras Kadioglu, David Knowles, Sigríður Ólafsdóttir, David Payne, Steve Projan, Sunil Shaunak, Jared Silverman, Christopher M Thomas, Trevor J Trust, Peter Warn & John H Rex. (2016) Alternatives to antibiotics—a pipeline portfolio review. The Lancet Infectious Diseases 16:2, pages 239-251.
Crossref
Crossref
Marcin Michalik, Bardya Djahanshiri, Jack C. Leo & Dirk Linke. 2016. Vaccine Design. Vaccine Design
87
106
.
Meenu Mishra, Adam Ressler, Larry S. Schlesinger & Daniel J. Wozniak. (2015) Identification of OprF as a Complement Component C3 Binding Acceptor Molecule on the Surface of Pseudomonas aeruginosa. Infection and Immunity 83:8, pages 3006-3014.
Crossref
Crossref
Kathryn J. Quigley, Catherine J. Reynolds, Amelie Goudet, Eleanor J. Raynsford, Ruhena Sergeant, Andrew Quigley, Stefan Worgall, Diana Bilton, Robert Wilson, Michael R. Loebinger, Bernard Maillere, Daniel M. Altmann & Rosemary J. Boyton. (2015)
Chronic Infection by Mucoid
Pseudomonas aeruginosa
Associated with Dysregulation in T-Cell Immunity to Outer Membrane Porin F
. American Journal of Respiratory and Critical Care Medicine 191:11, pages 1250-1264.
Crossref
Crossref
Qiang Shan, Markryan Dwyer, Samir Rahman & Mihaela Gadjeva. (2014) Distinct Susceptibilities of Corneal Pseudomonas aeruginosa Clinical Isolates to Neutrophil Extracellular Trap-Mediated Immunity. Infection and Immunity 82:10, pages 4135-4143.
Crossref
Crossref
Ignacio Mart?n-Loeches, Emili Diaz & Jordi Vall?s. (2014) Risks for multidrug-resistant pathogens in the ICU. Current Opinion in Critical Care 20:5, pages 516-524.
Crossref
Crossref